How would you approach a patient with metastatic HER2+ breast cancer on TDM-1 with progression in the breast and stable systemic disease?

Progression is progression whether it is in breast or distant sites. The question in my mind is that was there inadequate primary surgery of this breast or possibly a different clone of cells. Practically speaking this is often hard to distinguish. It would helpful to know if this a metastases that ...